Ping An Biomedical Co. Ltd. Overview
Ping An Biomedical is a Cayman-domiciled, Hong Kong-headquartered micro-cap that today operates a small, asset-light apparel supply-chain management (SCM) business in mainland China through its Shanghai subsidiary New Brand. That business sources and resells cashmere, wool, cotton and fancy yarns and, to a lesser degree, finished knitwear, coordinating third-party mills and contract manufacturers for brand owners, textile manufacturers, sourcing agents and online retailers. Revenue fell 61% in FY2025 to RMB34.1 million and declined a further 47% year-on-year in the first half of FY2026. Following its July 2025 IPO, a change of control-style leadership overhaul in October 2025, and a highly dilutive US$0.04-per-share placement in February 2026, management has rebranded the company toward biomedical and health technologies, signing a non-binding memorandum to invest in Future Biotechnology Group and a channel agreement in health services. The equity trades well below Nasdaq's US$1 minimum bid, with a compliance deadline of November 23, 2026.
Company's own description
In its FY2025 Form 20-F, the company describes itself as a holding company conducting operations through its PRC subsidiary New Brand, positioned as a provider of SCM services in the apparel industry offering one-stop solutions across yarn products, textiles and finished garments. The service scope covers market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The 20-F explicitly characterizes the model as "asset-light": substantially all products are produced by third-party contract manufacturers using raw materials the company sources from vendors, and the company holds ownership in only a very limited number of proprietary apparel products [Source: 20-F FY2025, Risk Factors].
The September 2025 rebranding press release added that the new name reflects a strategic focus on biomedical and healthcare technologies [Source: GlobeNewswire, September 12, 2025]. StockTitan's issuer profile now describes the company both as an apparel SCM provider and as focused on healthcare and biomedical technology.
Business model and revenue model
| Dimension | Characterization |
|---|---|
| Revenue type | Product sales (100%): sales of yarns and finished garments recognized at a point in time when goods are accepted by the customer [Source: 6-K H1 FY2026, Note 2] |
| Service vs. product | Economically a service (sourcing/coordination) business, but monetized through product resale margins rather than fees |
| Subscription / licensing | None disclosed |
| Payment terms | Customers typically pay within 40 to 90 days; goods deemed accepted if not returned within 15 days [Source: 6-K H1 FY2026] |
| Capital intensity | Minimal: gross PP&E of RMB99,255 (computer and office equipment) at September 30, 2025 [Source: XBRL, 20-F FY2025] |
| Gross margin profile | Thin: 5.1% (FY2023), 6.2% (FY2024), 2.8% (FY2025), 7.5% (H1 FY2026) |
| Seasonality | Finished garments peak August to December; yarns show no clear seasonality [Source: 20-F FY2025] |
Value chain position
The company sits between upstream fiber/yarn spinners and downstream garment producers or brand owners. It does not spin, knit or dye. Its value-add is trend interpretation, design, supplier selection, quality control and logistics coordination. This "middleman" position is structurally exposed to disintermediation; the 20-F itself notes brand owners increasingly order directly from manufacturers via online platforms.
Customer types and end markets
Customers span brand owners, textile manufacturers, apparel sourcing agents, and online fashion and garment retailers [Source: Renaissance Capital IPO profile]. Concentration is extreme: the top five customers accounted for 81% of revenue in FY2023, 86% in FY2024 and 91% in FY2025 [Sources: Renaissance Capital, October 2024; 20-F FY2025]. In H1 FY2026, the top three customers contributed 31.72%, 24.43% and 14.20% of revenue [Source: 6-K H1 FY2026]. All revenue is generated in the PRC (the company's definition of "China" includes Hong Kong).
Independent characterization
On the evidence of the filings, PASW is best characterized as a sub-scale yarn trading intermediary in structural decline, now serving primarily as a listed vehicle for a strategic pivot whose substance has not yet been demonstrated. Three facts support this view. First, revenue contracted from RMB87.6 million (FY2024) to RMB34.1 million (FY2025) to an annualized run-rate of roughly RMB19 million (H1 FY2026 doubled). Second, the H1 FY2026 return to profit was driven entirely by a RMB6.09 million credit-loss reversal and a RMB5.67 million fair-value gain on a listed equity investment; the core business generated only RMB0.54 million of operating income including that reversal, implying an underlying operating loss of about RMB5.5 million. Third, the "biomedical" business has no disclosed revenue, products, regulatory approvals or staff; its WFOE (Pingyuan Anjian Biotech (Hainan) Co., Ltd) was described as having no operations as of the H1 FY2026 report.
Strategy
Stated strategy themes
From the IPO-era materials and 20-F: (i) procure raw materials for textile and garment manufacturing; (ii) broaden the customer base; (iii) enhance efficiency and SCM capabilities; (iv) explore eco-friendly and sustainable raw materials; (v) broaden the sourcing chain; and (vi) fund working capital. These were the stated uses of IPO proceeds [Source: IPO closing press release, July 22, 2025].
From September 2025 onward, management's messaging shifted to biomedical and healthcare technologies, emphasizing corporate image and positioning in the industry [Source: press release, Sep 12, 2025]. No investor day has been held and no formal strategic plan document has been published.
Initiatives in the last 24 months
| Date | Initiative | Detail | Status |
|---|---|---|---|
| Jul 2025 | IPO | US$15.0M gross raised | Completed |
| Aug 2025 | Hainan biotech WFOE | Pingyuan Anjian Biotech formed | Dormant |
| Sep 2025 | Rebrand | Ping An Biomedical name and PASW ticker | Completed |
| Nov 2025 | Equity investments | Direct Booking Technology, Zhi Ding Group, Lanzhi Yunchuang Technology; RMB29.1M deployed by March 2026 | Completed (carrying value RMB41.25M) |
| Jan 2026 | Future Biotechnology Group memorandum | US$30M initial cash investment plus up to US$60M follow-on acquisitions (cash and escrowed consideration shares) | Non-binding |
| Jan–Mar 2026 | Equity raises | 100M shares at US$0.04; 567,000 at US$0.15 | Completed |
| Mar 2026 | Capital restructuring | Dual-class shares; share consolidation authority (StockTitan summary cites a conditional 1,000:1 ratio; press release leaves ratio to board) | Approved; consolidation not yet effected as of latest filing |
| Jul 2026 | Trademark acquisition | US$2.5M Hong Kong marks from related party | Completed |
| Jul 2026 | Health channel partnership | Yuan Sheng Mei Yan; RMB500M three-year cumulative sales target | Signed |
Guidance and targets
No revenue, margin or earnings guidance has been issued. The only quantified forward targets relate to counterparties: Future Biotechnology Group revenue thresholds of RMB750 million (2026), RMB1.3 billion (2027) and RMB2.3 billion (2028) govern escrow release, and the Yuan Sheng Mei Yan agreement targets RMB500 million cumulative sales over three years. Note the scale mismatch: the Future Biotechnology initial investment alone (US$30 million) is roughly double PASW's market capitalization and about six times its March 31, 2026 unrestricted plus restricted cash (about US$5.2 million). Funding sources for that commitment have not been disclosed.
ESG commitments and cost programs: none disclosed.
Products & Services
Apparel SCM (the only revenue-generating activity)
| Offering | Description | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Cashmere and cashmere-blend yarns | Sourced from third-party spinners and resold; the company's legacy specialty (New Brand's name references cashmere) | Knitwear manufacturers, brand owners | Since 2014 | Per-order fixed price; vendor cost agreed concurrently with customer order |
| Merino wool yarns | Sourced fine-wool yarns | Knitters, garment makers | Since 2014 | Per-order |
| Cotton yarns | Commodity and specialty cotton yarns | Garment makers | — | Per-order |
| Fancy yarns | Novelty and textured yarns | Fashion knitwear producers | — | Per-order |
| Silk inputs | Listed among raw materials | — | — | — |
| Finished garments (knitwear) | End-to-end coordination from trend analysis and design to contract manufacturing, QC and delivery | Brand owners, sourcing agents, online retailers | Since 2014 | Per-order |
| Market trend analysis | Bundled service | All customers | Not separately priced | Embedded in product margin |
| Product design and development | In-house design capability | Brand owners | Not separately priced | Embedded |
| Raw material sourcing | Supplier selection and procurement | All | Not separately priced | Embedded |
| Production and quality control | Inspection and rectification of contract output | Garment customers | Not separately priced | Embedded |
| Logistics management | Delivery coordination | All | Not separately priced | Embedded |
Named flagship brands: none disclosed. The company states it owns very few proprietary apparel products. The trademarks acquired in July 2026 (Hong Kong, US$2.5M, from Meridian Industries) are listed in a deed schedule; the specific marks were not visible in the filed exhibit.
Biomedical / health (announced, pre-revenue)
| Initiative | Description | Status | Source |
|---|---|---|---|
| Pingyuan Anjian Biotech (Hainan) | WFOE vehicle for biotech activities | No operations disclosed | 6-K H1 FY2026 |
| Future Biotechnology Group investment | Target described as engaged in biopharmaceutical R&D, genetic testing, medical devices and pharmaceutical sales | Non-binding memorandum only | Press release, Jan 9, 2026 |
| Yuan Sheng Mei Yan channel partnership | PASW to supply biotechnology products and technical support; partner provides health-management and wellness channels | Agreement signed; no revenue disclosed | 6-K, Jul 22, 2026 |
| Biotechnology product catalog | — | No products, specifications or approvals disclosed | — |
Note on third-party descriptions: Several low-quality syndicated websites describe PASW as an in-vitro diagnostics and precision-medicine company. No SEC filing reviewed supports that description, and it is disregarded here.
Financial Narrative
Coverage limitation: The company listed in July 2025, and its 20-F presents three years (FY2023–FY2025) of income and cash-flow data and two balance sheets (FY2024–FY2025). Tables therefore cover FY2023–FY2025 plus the H1 FY2026 interim period.
Income statement (RMB)
Sources: SEC XBRL company facts for the FY2025 20-F. Selling expenses derived as total operating expenses minus G&A minus credit loss provision. Tax sign convention normalized (expense positive). FY2025 EPS in USD was -0.10.
Margins and growth (%)
Revenue CAGR FY2023–FY2025: -35.7% per year (analyst calculation).
Interim comparison (six months ended March 31, RMB)
Source: 6-K H1 FY2026.
Commentary — income statement. FY2024 represented the high-water mark of a very low-margin model: revenue grew 6.1% to RMB87.6 million, but G&A rose 53% to RMB5.0 million (IPO preparation costs and listing readiness), wiping out operating income. FY2025 is the inflection: revenue collapsed 61% (H1 alone fell 60% year-on-year, from RMB45.7 million to RMB18.2 million), gross margin halved, and a RMB9.34 million credit-loss charge was taken as the allowance on receivables rose from RMB11.04 million to RMB15.16 million against gross receivables of RMB32.09 million (47% reserved). The deferred tax benefit of RMB1.86 million partially cushioned the result.
H1 FY2026 shows a reported swing to RMB4.83 million net income, but analysis of quality is essential. Removing the RMB6.09 million credit-loss reversal and RMB5.67 million fair-value gain yields an underlying pre-tax loss of approximately RMB5.48 million on revenue of RMB9.59 million. G&A rose 71% year-on-year to RMB4.54 million, including RMB1.44 million of amortized stock compensation from consultant options; selling expenses rose more than tenfold to RMB1.73 million despite halving sales, plausibly reflecting biomedical business development costs (not explained in the filing).
Balance sheet (RMB)
Sources: XBRL for 20-F FY2025; FY2025 line items confirmed against comparative column in 6-K H1 FY2026. Restricted cash at FY2024 derived as nil (total cash and restricted cash equaled unrestricted cash of RMB130,923).
Source: 6-K H1 FY2026.
Commentary — balance sheet. The IPO (US$15.2 million recorded as proceeds; RMB108.2 million gross in XBRL) transformed a negative-equity balance sheet into RMB45.2 million of equity. However, the cash was overwhelmingly restricted (RMB35.5 million of RMB36.7 million), and the reason for the restriction is not explained in the reviewed sources. By March 31, 2026, RMB29.1 million of cash had been deployed into equity investments (Direct Booking Technology Co., Ltd, a listed investee; Zhi Ding Group Co Limited; and Lanzhi Yunchuang Technology (Beijing) Co., Ltd). Equity investments now represent 41% of total assets, meaning reported book value is increasingly a function of investee valuations rather than operating assets. The carrying value of RMB41.25 million exceeds cash outlay plus fair-value gain (RMB34.80 million) by about RMB6.45 million; the reconciling item is not disclosed in reviewed material.
Cash flow (RMB)
Sources: XBRL. Capex inferred as nil because gross PP&E was unchanged at RMB99,255 between September 30, 2024 and September 30, 2025. FY2025 income taxes paid not disclosed in XBRL; shown as 0 for charting only.
H1 FY2026: operating cash flow RMB1.14 million; investing outflow RMB29.13 million (equity investments); financing inflow RMB28.41 million (share issuance RMB28.62 million; related-party loans RMB10.80 million drawn and RMB11.01 million repaid) [Source: 6-K H1 FY2026].
Commentary — cash flow. Operating cash flow is dominated by working-capital swings in receivables and payables rather than earnings. FY2024's positive RMB14.6 million OCF was largely a release of prepayments and payables timing, used along with investing inflows to repay RMB30.1 million of financing. The business has never been capital intensive. The defining cash-flow feature since listing is that external equity (IPO and placements) has been redeployed into minority equity stakes and a related-party trademark purchase rather than into the operating business.
Ratios
Analyst calculations from XBRL data. FY2024 ROE and ROIC shown as 0 because equity was negative (not meaningful). FY2025 ROIC approximated as after-tax operating loss (operating loss less 25% statutory tax) over equity plus borrowings. Net debt/EBITDA not meaningful in both years (FY2025 net cash; negative EBITDA).
Interpretation. Receivable days of 170–180 days in a business with contractual terms of 40–90 days indicate chronic collection problems, consistent with the 47% allowance. Payables stretched to over 100 days in FY2025, suggesting the company leaned on suppliers as revenue contracted.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Ownership | Function |
|---|---|---|---|
Ping An Biomedical Co., Ltd. | Cayman Islands | Listed parent | Holding company |
Nifty Holdings Limited | BVI | 100% by parent | Investment holding |
Multi Ridge (Asia) Limited | Hong Kong | 100% by Nifty | Investment holding; purchaser of trademarks (July 2026) |
New Brand Cashmere Products Co., Ltd | PRC (Shanghai) | 100% by Multi Ridge | Operating company: trading of yarns and finished garments |
Pingyuan Anjian Biotech (Hainan) Co., Ltd | PRC (Hainan) | 100% by Multi Ridge | Established August 27, 2025; no operations as of H1 FY2026 report |
Segment / Product Line Details
| Segment / product line | Contents | Products |
|---|---|---|
Sales of Yarns | Sourcing and resale of yarns to knitters and garment makers | Pure cashmere and cashmere-mix yarns, merino wool, cotton, fancy yarns |
Sales of Finished Garments | Design-to-delivery coordination of knitwear produced by contract manufacturers | Knitwear and finished garments for brand owners and online retailers |
Product Lines
| Product line (H1 FY2026, six months to Mar 31, 2026) | Revenue (CNY Mn) | % of total |
|---|---|---|
Sales of Yarns | 8.84 | 92 |
Sales of Finished Garments | 0.76 | 8 |
Total | 9.59 | 100 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (CNY Mn) | 82.56 | 87.62 | 34.15 |
YoY growth (%) | 0 | 6.1 | -61.0 |
Gross profit (CNY Mn) | 4.24 | 5.42 | 0.95 |
Gross margin (%) | 5.1 | 6.2 | 2.8 |
Income Statement (CNY) and Per-Share Data
| Metric (MYR Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Revenue | 82,563,751 | 87,622,395 | 34,147,936 |
Cost of revenue | 78,323,583 | 82,205,508 | 33,198,431 |
Gross profit | 4,240,168 | 5,416,887 | 949,505 |
Selling expenses (derived) | 332,508 | 306,582 | 299,959 |
General and administrative expenses | 3,265,341 | 4,992,481 | 6,007,792 |
Credit loss provision | 29,838 | 119,863 | 9,343,225 |
Total operating expenses | 3,627,687 | 5,418,926 | 15,650,976 |
Operating income (loss) | 612,481 | -2,039 | -14,701,471 |
Depreciation | 32,756 | 10,239 | 5,585 |
EBITDA (operating income plus depreciation) | 645,237 | 8,200 | -14,695,886 |
Interest expense | 1,740,259 | 705,273 | 307,055 |
Interest income | 156,142 | 2,034 | 326,349 |
Other non-operating income | 1,013,322 | 110,435 | 41,966 |
Pre-tax income (loss) | 41,686 | -682,716 | -14,684,795 |
Income tax expense (benefit) | 1,035,623 | 601,456 | -1,855,589 |
Net income (loss) | -993,937 | -1,284,172 | -12,829,206 |
EPS basic and diluted (MYR Bn) | -0.06 | -0.07 | -0.69 |
Dividends per share (MYR Bn) | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Gross margin | 5.14 | 6.18 | 2.78 |
Operating margin | 0.74 | 0.00 | -43.05 |
EBITDA margin | 0.78 | 0.01 | -43.04 |
Pre-tax margin | 0.05 | -0.78 | -43.00 |
Net margin | -1.20 | -1.47 | -37.57 |
G&A as % of revenue | 3.95 | 5.70 | 17.59 |
Revenue growth YoY | 0 | 6.13 | -61.03 |
Income Statement (CNY) and Per-Share Data (Half-Yearly)
| Metric (MYR Bn) | H1 FY2025 | H1 FY2026 |
|---|---|---|
Revenue | 18,230,963 | 9,594,250 |
Gross profit (loss) | -692,318 | 723,357 |
Selling and marketing | 151,338 | 1,734,519 |
General and administrative | 2,647,992 | 4,537,652 |
Credit loss provision (reversal) | 125,888 | -6,086,418 |
Operating income (loss) | -3,617,536 | 537,604 |
Fair value gain on equity investment | 0 | 5,673,782 |
Pre-tax income (loss) | -3,738,241 | 6,283,707 |
Income tax expense | 494,878 | 1,457,734 |
Net income (loss) | -4,233,119 | 4,825,973 |
EPS basic and diluted (MYR Bn) | -0.24 | 0.10 |
Weighted average shares | 18,000,000 | 50,530,258 |
Balance Sheet (CNY)
| Metric (MYR Bn) | FY2024 | FY2025 |
|---|---|---|
Total assets | 56,849,755 | 68,414,527 |
Current assets | 53,310,118 | 63,697,447 |
Cash and bank balances (unrestricted) | 130,923 | 1,172,480 |
Restricted cash | 0 | 35,523,810 |
Accounts receivable, gross | 51,483,121 | 32,092,210 |
Allowance for credit losses | 11,041,825 | 15,161,334 |
Accounts receivable, net | 40,441,296 | 16,930,876 |
Deposits, prepayments and other receivables | 12,603,304 | 9,628,377 |
Inventories | 127,296 | 441,904 |
Deferred tax assets | 2,722,233 | 4,249,503 |
Goodwill and intangibles | 0 | 0 |
Current liabilities | 63,576,483 | 23,076,822 |
Short-term bank borrowings | 0 | 10,000,000 |
Accounts payable | 15,055,820 | 9,413,410 |
Total liabilities | 64,037,936 | 23,172,520 |
Shareholders' equity (deficit) | -7,188,181 | 45,242,007 |
Working capital | -10,266,365 | 40,620,625 |
Net debt (borrowings less cash incl. restricted) | 0 | -26,696,290 |
Balance Sheet (CNY) (Mar 31, 2026)
| Metric (MYR Bn) | Mar 31, 2026 |
|---|---|
Total assets | 100,222,250 |
Cash and bank balances | 6,842,381 |
Restricted cash | 29,144,050 |
Accounts receivable, net | 6,188,887 |
Equity investments | 41,246,798 |
Short-term bank borrowings | 10,000,000 |
Other payables, related parties | 3,037,926 |
Total liabilities | 22,040,208 |
Shareholders' equity | 78,182,042 |
Working capital | 33,870,564 |
Cash Flow (CNY)
| Metric (MYR Bn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Operating cash flow | -6,082,836 | 14,630,221 | -6,427,762 |
Investing cash flow | -3,367,570 | 15,000,000 | 0 |
Financing cash flow | 8,874,664 | -30,088,905 | 43,660,424 |
Interest paid | 1,950,750 | 705,274 | 310,891 |
Income taxes paid (refunded) | 2,124,332 | -220,865 | 0 |
Cash Flow (CNY) (FY2024–FY2025)
| Metric (MYR Bn) | FY2024 | FY2025 |
|---|---|---|
Capital expenditure | 0 | 0 |
Free cash flow (OCF less capex) | 14,630,221 | -6,427,762 |
Dividends paid | 0 | 0 |
Share buybacks | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROE (net income / ending equity, %) | 0 | -28.36 |
ROA (net income / ending assets, %) | -2.26 | -18.75 |
ROIC (%) | 0 | -26.6 |
Current ratio (x) | 0.84 | 2.76 |
Debt / equity (x) | 0 | 0.22 |
Net debt / EBITDA (x) | 0 | 0 |
Interest coverage, EBIT / interest (x) | 0.00 | -47.88 |
Asset turnover, revenue / ending assets (x) | 1.54 | 0.50 |
Days sales outstanding | 168.5 | 181.0 |
Days inventory outstanding | 0.6 | 4.9 |
Days payables outstanding | 66.8 | 103.5 |
Cash conversion cycle (days) | 102.3 | 82.4 |
Revenue by Region (%)
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
PRC including Hong Kong (% of revenue) | 100 | 100 | 100 |
Rest of world (% of revenue) | 0 | 0 | 0 |
Share Price & Returns
| Reference point | Price (USD) | Source |
|---|---|---|
IPO price (Jul 17, 2025) | 6.00 | Press release |
First-day close (Jul 18, 2025) | 3.30 | IPOScoop |
Jul 25, 2025 close | 1.81 | AlphaQuery |
Oct 1, 2025 | 1.24 | StockTitan |
Apr 1, 2026 | 0.13 | Seeking Alpha |
Apr 14, 2026 | 0.16 | Trendlyne |
Aug 4, 2026 | 0.13 | MarketChameleon |
Sep 24, 2026 | 0.13 | Benzinga |
Metric | Value | — |
Return since IPO price | Approximately -97.8% (analyst calculation, US$6.00 to US$0.13) | — |
1-year return | Not meaningful / approximately -90% from Oct 1, 2025 level of US$1.24 | — |
3-year and 5-year returns | Not applicable (listed July 2025) | — |
52-week range | US$0.11–US$1.32 (Benzinga, Sep 2026) | — |
Beta | 0.09 (MarketChameleon; low reliability given liquidity) | — |
Average weekly volatility | About 30% (Simply Wall St) | — |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Market capitalization (USD Mn) | 16.3 | 125.117M shares |
Enterprise value (USD Mn) | 12.5 | Market cap plus US$1.45M borrowings less US$5.22M cash and restricted cash (Mar 31, 2026) |
EV/Sales (TTM) | About 3.4x | TTM revenue about RMB25.5M (about US$3.7M) |
P/B | About 1.4x | Book equity US$11.33M at Mar 31, 2026 |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | No sell-side coverage identified |
Dividend policy | No intention to pay dividends in the near future (20-F) |
Buyback authorizations | None, other than the approved repurchase-and-issue exchange with INSPIRETECH (non-cash) |
Debt maturity profile | RMB10.0M short-term bank borrowings (Bank of China; XBRL tags reference May 19, 2026); still outstanding at March 31, 2026; current status post-May 2026 not disclosed |
Equity issuance history | IPO 2.5M at US$6.00 (Jul 2025); 4.05M option shares to consultants (Nov 2025); 100M at US$0.04 (Feb 2026); 567,000 at US$0.15 (Mar 2026) |
Authorized capital | US$312,500: 4.9B Class A and 100M Class B shares (post-AGM) |
Pending consolidation | Board authority within one year of March 18, 2026; ratio at board discretion (StockTitan summary references 1,000:1 conditional) |
Analyst Conclusions
Management guidance
None. Management stated in the H1 FY2026 report that existing resources are sufficient for at least 12 months of operations, while acknowledging macro and demand uncertainty. Consensus growth expectations: none (no coverage).
Bull case (grounded in data)
-
Clean balance sheet with optionality: RMB78.2M of equity, net cash of about RMB26M including restricted cash, and a market capitalization of about US$16M mean the market pays a modest premium to book for a listed platform with recognized strategic investors.
-
Credible upside if the Future Biotechnology deal becomes definitive: The escrow structure ties consideration shares to audited revenue of RMB750M in 2026 rising to RMB2.3B in 2028, with unearned tranches cancelled; if executed on those terms, PASW would acquire revenue many times its current scale with partial performance protection.
-
Credit recovery and investment gains: H1 FY2026 already showed RMB6.09M of reserve reversals and a RMB5.67M investment gain; further collections and a rising listed investee could continue to support reported earnings and book value.
Bear case (grounded in data)
-
Core business is disappearing: Revenue fell from RMB87.6M (FY2024) to an annualized ~RMB19M (H1 FY2026); underlying H1 FY2026 pre-tax loss of about RMB5.5M excluding one-offs.
-
Shareholder-unfriendly capital actions: A placement at US$0.04 (versus a market price several times higher in the same period) increased the share count roughly fivefold; consultant options added 4.05M shares; a 100-vote Class B structure was approved for a holder of under 10% of economic interest; and US$2.5M was paid to a Controlling Shareholder-linked entity for trademarks of undisclosed specification.
-
Listing and execution risk: The stock needs roughly an 8x price increase (or a large reverse split) by November 23, 2026; the Future Biotechnology memorandum remains non-binding and the US$30M initial commitment exceeds available cash several times over.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| Nasdaq bid-price deadline | Nov 23, 2026 | Announcement and ratio of share consolidation; Nasdaq panel request if missed |
| FY2026 Form 20-F | By end-January 2027 (120 days after Sep 30 FYE) | First audit by Edston Global PAC; going-concern opinion; segment disclosure; equity investment valuations |
| Future Biotechnology Group | Ongoing | Definitive agreement, funding source, CSRC filings, consideration share count |
| Yuan Sheng Mei Yan channel | Ongoing | First biomedical revenue recognition; product identification and regulatory approvals |
| Class B issuance | Ongoing | Whether INSPIRETECH exchange is executed; resulting voting power |
| Related-party flows | Ongoing | Further transactions with Meridian, Wisewing and other Controlling Shareholder entities |
| Bank borrowings | Ongoing | Renewal or repayment of RMB10M Bank of China facility |
| Equity investments | Semi-annual | Mark-to-market of Direct Booking Technology and other investees |
| Resale registrations | Ongoing | Selling-holder supply overhang (13.61M shares reported) |
Analyst verdict
Ping An Biomedical is, on the evidence available, a shell-like listed vehicle attached to a shrinking yarn-trading operation, now marketed as a biomedical platform. The apparel SCM business that justified the July 2025 IPO lost 61% of its revenue in the first full fiscal year of listing and almost half again in the following half-year, and it operates at gross margins that leave no room for a public-company cost base. The FY2025 audited loss of RMB12.8 million and the underlying H1 FY2026 loss of roughly RMB5.5 million, once credit-loss reversals and a single investment mark are stripped out, describe a business that does not earn its keep.
The investment case therefore rests entirely on the pivot and on capital allocation by a management team installed in October 2025. So far the record is concerning. Capital raised has gone into minority stakes in technology companies whose connection to biomedicine is unexplained, into a US$2.5 million trademark purchase from an entity controlled by a founding shareholder, and into stock compensation for consultants. The February 2026 placement at four US cents per share transferred roughly 80% of the company's economic ownership to unnamed private-placement investors at a deep discount, and the approved dual-class structure could concentrate over 90% of voting power in an entity linked to the CEO. The headline Future Biotechnology Group transaction remains a non-binding memorandum whose initial cash component alone dwarfs the company's resources.
Disclosure quality is also weak: stale risk-factor figures, a 6-K cover that mischaracterizes the counterparty to a related-party deal, an unexplained RMB35.5 million restricted-cash balance, and an unreconciled gap in equity investment carrying values.
Verdict: high risk, speculative, and not investable on fundamentals. Monitor only for a definitive, independently funded biomedical transaction, the outcome of the November 2026 Nasdaq deadline, and the first audit by the new auditor.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Appointed | Born | Education | Prior roles |
|---|---|---|---|---|---|
Pijun Liu | Chairman, CEO, Executive Director | Oct 14, 2025 | 1,982 | Bachelor's, Wuhan University of Technology; Master's in Computer and Information Technology, University of Arizona; postgraduate study at Renmin University School of Finance (2018–2020); Tsinghua EMBA program | Project manager at eLong.com (2004–2007); founder and CEO of Yueshang Group (2014–2023) |
Hongli Yang | Chief Financial Officer | Oct 14, 2025 | 1,995 | Bachelor's in Financial Management, Xiangtan University | CFO roles since 2021 at Softcom Information Technology (Group), Beijing Sinobo Information Technology, and Huibo Cloud Communication Technology; also a director of Multi Ridge (signatory to July 2026 deed) |
Xianzhi Liu | Independent Director | Oct 14, 2025 | 1,997 | Bachelor's in Electronic Science and Technology, North University of China; Master's in Mechatronics and Robotics, University of Leeds | JD.com (2022); Beijing New Oriental Education Consulting (2023–2024); New Channel, Zhejiang headquarters (2025–) |
Board of Directors — Yuk Yin Judy Li
| Name | Former role | Departure | Stated reason |
|---|---|---|---|
Yuk Yin Judy Li | Chair and Director (also a Controlling Shareholder) | October 2025 | Personal reasons; no disagreement |
Lina Jiang | CEO and Director | October 2025 | Personal reasons; no disagreement |
Xueyuan Chen | CFO | October 2025 | Personal reasons; no disagreement |
Taylor Carl Coplen | Independent Director | October 2025 | Personal reasons; no disagreement |
Governance Overview
| Attribute | Status |
|---|---|
Chair / CEO separation | Combined (Pijun Liu holds both roles) |
Home-country practice exemptions | 20-F states none currently relied upon |
Dual-class structure | Approved March 18, 2026: 4.9 billion Class A and 100 million Class B authorized; StockTitan summary indicates Class B carries 100 votes per share |
Insider trading policy, code of ethics | Adopted at IPO |
Material weakness in ICFR | Disclosed (segregation of duties; governance) |
Major Shareholders
| Holder | Shares | % of 125,117,000 | Source / note |
|---|---|---|---|
INSPIRETECH LTD (indirect holding of CEO Pijun Liu) | 12,250,000 | 9.8 | Form 3, April 8, 2026 |
Purchasers of 100,000,000-share private placement (accredited / Regulation S investors) | 100,000,000 | 79.9 | 6-K, Feb 12, 2026; individual allocations not disclosed |
Purchasers of March 2026 placement | 567,000 | 0.5 | 6-K H1 FY2026 |
Six consultants (exercised options) | 4,050,000 | 3.2 | 6-K H1 FY2026; may since have been sold |
IPO public float | 2,500,000 | 2.0 | Prospectus |
Institutional holders (13F) | — | Negligible | No material institutional ownership identified |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning relative to PASW |
|---|---|---|
Shenzhou International Group (HKEX: 2313) | Knitwear manufacturing for global brands | Vertically integrated giant; incomparable scale |
Crystal International Group (HKEX: 2232) | Apparel manufacturing and supply | Multinational manufacturer with brand-owner relationships |
Texhong International (HKEX: 2678) | Yarn production | Large spinner; illustrates industry margin compression (yarn gross margin under 1% in H1 2023 per Benzinga) |
Ordos / Erdos Resources (SSE: 600295) | Cashmere products | Integrated cashmere brand and processor |
Consinee Group (private, Ningbo) | Cashmere and fine-wool yarns | Specialist spinner selling direct to knitters |
Novetex Textiles (private, Hong Kong) | Yarn spinning | Direct supplier to knitters |
Li & Fung (private since 2020) | Global sourcing and SCM | Category-defining sourcing intermediary |
Addentax Group (Nasdaq: ATXG) | Garment manufacturing, logistics and related services in China | Comparable U.S.-listed China micro-cap |
B2B online sourcing platforms (e.g., Alibaba 1688) | Direct manufacturer ordering | Primary disintermediation threat cited in 20-F |
Peer Comparison FY2025
| Metric | PASW (FY2025) | Texhong International |
|---|---|---|
Revenue | RMB34.1M | — |
Revenue growth | -61.0% | — |
Gross margin | 2.8% | Low single digits in 2023 per Benzinga |
Net margin | -37.6% | Loss-making in 2023 per Benzinga |
R&D intensity | 0% | — |



